Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES

Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults

(2019) Luanluan Sun et al.   NATURE MEDICINE

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial

(2019) J. Wouter Jukema et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid levels and the risk of hemorrhagic stroke among women

(2019) Pamela M. Rist et al.   NEUROLOGY

Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage

(2019) Chaoran Ma et al.   NEUROLOGY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

(2014) Walter N. Kernan et al.   STROKE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal Hemorrhage

(2009) Hiroyuki Noda et al.   CIRCULATION

Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial

(2009) Larry B. Goldstein et al.   STROKE